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Piperazine derivatives as dangerous abused compounds
Piperazine derivatives are a group of compounds with a 
psychostimulant effect. They are an alternative to illegal 
drugs. They are being searched for recreational use due to 
their psychoactive and hallucinogenic effects. The high 
popularity of these compounds can be noticed all over the 
world due to easy purchase, lack of legal regulations and 
incorrect assessment of the safety of use. The recreational 
use of piperazine derivatives can often result in chronic 
and acute health problems and additionally with unpre-
dictable remote effects. It is also common to take mixtures of 
psychoactive compounds. This hinders the correct diagnosis 
and treatment of patients with poisoning. The presented 
work is an illustration of the wide problem of pipe razine 
derivatives abuse. The health effects and the possi bility of 
identifying these compounds in preparations and biological 
material are described.
Keywords: piperazine derivatives, designer drugs, benzyl-
piperazine, phenylpiperazine, addiction
INTRODUCTION
Available literature data indicates a growing interest in new psychoactive substances 
(NPS) around the world (1, 2). These products, often called designer drugs, can be divided 
into three main groups: piperazine derivatives, ketoarylamines and synthetic cannabi-
noids. The modified chemical structures of these compounds aim to mimic the pharmaco-
logical effects of illicit drugs and trigger potential abuses. The problem of today is consumers 
experimenting with these substances in order to achieve a specific benefit (3, 4). Access to 
NPS is easy and without an atmosphere of legal sanctions. Designer drugs are characterized 
by a diverse composition and are often combined with other mixtures and forms of psycho-
active compounds (5, 6).
Piperazine derivatives can be divided into two classes: benzylpiperazine derivatives 
and phenylpiperazine derivatives (1, 4, 7). In previous years, studies were undertaken to 
clarify the properties of piperazine compounds. In the 70th and 80th benzylpiperazine and 
its derivatives were repeatedly tested as antidepressants. They did not find a medical 
appli cation because of their amphetamine-like effects, even though they were less intense. 
Some piperazine derivatives have been identified as active metabolites of the therapeutic 
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drugs (7, 8). For example, mCPP [1-(3-chlorophenyl)piperazine] is a metabolite of psycho-
tropic drugs such as trazodone, nefazodone, etoperidone and mepiprazole. MDBP 
[1-(3,4-methylenedioxybenzyl)piperazine] is the major metabolite of therapeutic drug 
 fipexide, which has been withdrawn due to adverse reactions, including liver toxicity. 
Another MeOPP [1-(4-methoxyphenyl)piperazine], phenylpiperazine derivative, was used 
in an in vivo study with Wistar rats (7). It was metabolised to N-acetyl-4-hydroxyaniline 
which corresponds to analgesic acetaminophen (paracetamol). The characteristic ring of 
piperazine is also found in the structure of various therapeutic drugs, for example, clozapine, 
imatinib, trimetazidine (9–14). For these therapeutic drugs, therapeutic efficacy and undesired 
events are monitored, and the analytical methods that are developed serve qualitative and 
quantitative determination. Recent studies indicate a great interest in compounds containing 
the ring of piperazine (15). The relationships between the chemical structure of piperazine 
derivatives and effects on the body are analysed. 
Piperazine derivatives are sought by users for recreational purposes due to their psycho-
active and hallucinogenic effects, unusual perception and experience after ingestion (7). 
The use of piperazine derivatives may result in the development of serious health problems. 
There are known cases of hospitalizations due to adverse events. Even a single use can lead 
to dangerous poisoning or death (8). Although many studies have been carried out, toxi-
cokinetic and toxicodynamic knowledge is still limited. In many hospitals, the majority of 
patients do not have analytical confirmation of poisoning (7, 16). The most important is the 
correct identification of these substances in biological and non-biological matrices, proper 
diagnostics of patients and effective medical help (7, 17, 18). The abuse of piperazine deri vatives 
is dangerous especially because these substances can be freely sold in many countries and 
on the Internet.
The presented work is an illustration of the modern problem of the abuse of pipera-
zine designer drugs and serious health consequences resulting from it. The possibilities of 
using the latest technologies to analyse these substances in preparations and biological 
material are presented. This review also shows the striving of scientists to fully under-
stand the effects of piperazine compounds on the human body. The collected information 
can be the basis for further, targeted research.
PIPERAZINE DERIVATIVES IN DESIGNER DRUGS
Considering the chemical structure, piperazine compounds are derived from pipera-
zine, a cyclic molecule with two nitrogens in the opposite position and four carbon atoms 
occurring between the two nitrogen atoms (7, 19, 20). The most popular piperazine deriva-
tives present in designer drugs are benzylpiperazine derivatives, e.g., N-benzylpiperazine 
(BZP), 1-(3,4-methylenedioxybenzyl)piperazine (MDBP), 1-(4-fluorobenzyl)piperazine 
(pFBP), 1,4-dibenzylpiperazine (DBZP) and phenylpiperazine derivatives, e.g., 1-(3-trifluoro-
methylphenyl)piperazine (TFMPP), 1-(3-chlorophenyl)piperazine (mCPP), 1-(4-parafluoro-
phenyl)piperazine (pFPP) and 1-(4-methoxyphenyl)piperazine (MeOPP). Table I presents the 
structural formulas of piperazine and the most popular piperazine derivatives occurring in 
designer drugs. Other derivatives of benzyl and phenylpiperazine, which may be compo-
nents of preparations of designer drugs are: 1-(2,3-dichlorophenyl)piperazine (2,3-DCPP), 
1-(4-bromo-2,5-dimethoxybenzyl)piperazine (2C-B-BZP), 1-benzyl-4-methylpiperazine 
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(MBZP), 1-(3-chlorophenyl)-4-(3-chloropropyl)piperazine (mCPCPP), 1-(3-methylbenzyl)pi-
perazine (MeBP) and 1-methyl-3-phenylpiperazine (MePP).
The most common names of preparations containing piperazine derivatives are: Fren-
zy, Legal X, Legal E, Bliss, A2, Rapture, Charge and Herbal Ecstasy; other common trade 
names are: Benny Bear, Flying Angel, Twisted, Jax, Nemesis and Red Eye Frog (7, 21, 22). 
While browsing Internet forums, you can still find various other names, forms and doses 
of preparations containing piperazine derivatives. Some products containing pFPP (also 
known as fluoperazine, flipiperazine, 4-FPP), are called: The Big Grin, Mashed, Extreme 
Beans, Playboy Bunny Tablets, Retro pills, Lab-X. Offered doses range from 20 to 150 mg. 
The sophisticated preparations under the name Cherries contained pFPP and TFMPP. 
Products containing mCPP were found under the names: Arlequin, X4, Rolls Royce or 
Smarties (23). Depending on the quantitative combination of BZP and TFMPP, the follow-
ing product names can be listed: Bliss, Clear Light, Combo, Exodus and The Good Stuff 
(24). A combination of up to four different piperazine derivatives was also found, which 
had the names: Party Pills, PEP and X4 (5). Tablets with mCPP can have various colours 
and logos, e.g., Mitsubishi, Lacoste (8). 
Piperazine derivatives in designer drugs are often found together with other psycho-
active substances, for example, ecstasy, cocaine, amphetamine, ketamine, cannabis (5, 25). 
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They can also be included in tablets sold to consumers as ecstasy or amphetamine. There 
have also been found alcohol solutions of piperazines and mixtures of piperazines in various 
quantitative proportions with derivatives of cathinones and synthetic cannabinoids (2, 23). 
Amphetamines may increase the stimulatory effect of BZP (2). Simultaneous alcohol con-
sumption may be associated with the sobering effects caused by piperazine derivatives. 
The negative effects of using other party pills can be well tolerated with the simultaneous 
use of BZP. Taking BZP with cannabis derivative is likely to induce users to relax, stimulate 
appetite and improve sleep. They are often used together with BZP: caffeine, herbal extracts, 
electrolyte mixtures and amino acids. For example, l-tyrosine, which is a precursor of 
dopamine, can be taken to counteract the depletion of dopamine. 
The usual doses of BZP are in the range of 50 to 250 mg (26). They result in effects last-
ing from 6 to 8 hours. It has been observed that the onset of BZP activity may be delayed 
up to 2 hours. This may be the cause of an increased risk of an overdose of this compound 
due to users taking multiple doses before the onset of effect. Cohen and Butler (27) in their 
study draw attention to the analytically identified level of BZP in party pills which was 
between 28 and 133 mg, with an average level of 65 mg per tablet. They also indicate reports 
on higher levels of BZP up to 1000 mg. They suggest that BZP could be detected in the 
blood up to 30 hours after ingestion. They also noted that BZP in party tablets often occurs 
in combination with TFMPP in a ratio of 2:1 to 10:1. The quantitative proportions were 100 mg 
BZP and 30 mg or 50 mg TFMPP, and 80 mg BZP and 40 mg TFMPP (24, 28). The mCPP 
content in the example of the analysed tablet was 45.8 mg (8).
The components of designer drugs are often contaminants or substances added to 
interfere with rapid diagnostic tests (29). These are easily publicly available products, 
among which can be mentioned: bleach, table salt, detergents, vinegar, lemon juice, hydro-
gen peroxide and many other commonly harmful substances. Ingredients may also in-
clude medicinal products containing psychoactive substances (30). Among such active 
ingredients are dextromethorphan (codeine substitute), benzydamine, ephedrine and 
pseudoephedrine. New psychoactive substances may also contain natural products such 
as plant fragments, cacti and animal venom (31).
There is currently a very large number of products containing piperazine derivatives 
on the market. The qualitative and quantitative composition of designer drugs changes 
constantly to avoid legal verification. In addition, it is possible to modify the chemical 
structures of the compounds presented above. All that gives access to creating hundreds 
of new products with potential psychoactive effects. Therefore, it is necessary to monitor 
the global market in the case of designer drugs. According to the European Drug Report 
(32), piperazine derivatives are on the list of products being subjected to frequent confisca-
tion. Piperazine derivatives are compounds with high potency and pose a serious threat 
to public health.
CONSUMER’S PROFILE OF PIPERAZINE DESIGNER DRUGS
The formulations containing piperazine derivatives are most often sold as party pills 
(5, 27). They are offered for sale also in the form of powder, capsules, tablets, smoking forms, 
liquid mixtures and injections (1). They produce stimulating and hallucinogenic effects and 
they are designed to imitate the effects of ecstasy (1, 18, 27). Abuse of party pills usually 
takes place in pubs, bars, at dance parties or rave music concerts, on the beach, in the park 
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or simply in the street (27). Synthetic substances, together with the desired sensations, can 
also create a number of unwanted and sometimes unsafe effects on consumers (1). 
Ren et al. (18) noticed that, despite economic growth, there was some serious malaise, 
especially among young people and children. They emphasized that the younger genera-
tion is dependent on new stimulants of TFMPP, mCPP and other piperazine designer 
drugs. In recent years, an increase in the abuse of piperazines has been reported in New 
Zealand, America and Japan. Lack of legal regulations and the susceptibility of young 
people to taking such compounds may lead to an uncontrolled threat of spreading new 
psychoactive substances.
Schifano et al. (4) stressed that the growing number of stimulants and parallel changes 
in the patterns of their use pose a challenge for psychiatry. People are susceptible to 
 taking these substances to improve the performance of the body, improve the image, the 
intensity of psychoactive activities and the probable lack of detection in routine screening. 
It was also suggested that the increase of interest in a particular psychoactive compound 
is preceded by the occurrence of clinical events at the level of population. The role of the 
Internet in shaping the supply market and exchange of experience was underlined (33, 34). 
The problem with consumers of designer drugs is that they take the risk of experimenting 
with new substances (3). That decision is made in order to achieve a specific benefit: a state 
of pleasure, relaxation, unreality or forgetfulness. It can also be a way to reduce pain and 
suppress feelings of guilt, suppress anxiety and unpleasant memories. The attitude of  society 
is focused on quick methods of acting, which is why young people often reach for quick 
and risky solutions. An additional problem is the lack of knowledge of the actual chemical 
components contained in psychostimulants. There is often a lack of information on meta-
bolism, addiction potential and serious adverse effects resulting from unexplored acute 
and chronic NPS toxicity (35).
The abuse of BZP was also observed among students as well as shift workers and 
truck drivers in order to increase vigilance, improve physical and mental fitness (2). It was 
used as an appetite suppressant as well as in the sports to improve performance (36). 
In New Zealand, a population survey was carried out to assess the impact of BZP 
banning. Wilkins and Sweetsur (37) presented a comparison between the levels of use BZP 
both before and after the introduction of the ban. They also analysed the reasons why users 
decided to stop using BZP. In addition to health concerns, the individual decisions related 
to the use of psychoactive substances are influenced by youth and culture trends, changes 
in accessibility and prices, changes in legal regulations, stringent controls and a targeted 
law enforcement campaign. It was observed that unpleasant side effects and the ban intro-
duction led to a decline in the use of BZP in New Zealand. 
The latest technological advances, easy access to various information via the Internet 
and the development of trade contribute to the growing popularity of branded drugs. On 
the other hand, everyday life brings a high pace of life, nervousness and quick pursuit of 
the goal. Also, people are constantly following new products and fashion, which reduces 
vigilance for the risks associated with NPS. The search for positive mood effects such as 
feelings of relaxation and pleasure is the main reason for using piperazine designer drugs. 
The more people succumb to such a habit, the stronger their dependence on psychostimu-
lants becomes. The potential of NPS to cause the damage may also result from the lack of 
experience of users in the field of, e.g., dosage. Lack of specific knowledge about the effects 
of psychostimulants is also a cause of many health and social problems. 
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PHARMACOLOGICAL PROFILES OF PIPERAZINE DERIVATIVES
In the pharmacological profile studies, piperazine derivatives were evaluated as com-
pounds leading to an increase in dopamine (DA), serotonin (5-HT) and noradrenaline (NA) 
levels (1). New psychoactive substances can cause the release of monoamines through exocy-
tosis and the process of non-exocytosis (38). In addition, they may increase the level of mono-
amines by inhibiting reuptake, reversing the transporter stream, blocking the transporter, and 
agonistic activity in postsynaptic receptor sites (38, 39). The influence of piperazine derivatives 
on DAT transporters (dopamine reuptake transporter), SERT (serotonin reuptake transporter) 
and NET (norepinephrine reuptake transporter) was analysed (38). Increased levels of DA, 
5-HT and NA neurotransmitters can cause desirable as well as adverse behavioural and clini-
cal effects. Increased level of dopamine is the cause of strengthening and behavioural-stimu-
lating effects (40). Elevated levels of norepinephrine can have effects on the cardiovascular 
system (tachycardia, hypertension) (38). Analogously, an increased level of serotonin can be 
the cause of entactogenic effects and life-threatening serotonin syndrome (38, 41). In addition, 
every mood-changing compound used has addiction potential (42). Among the piperazine 
derivatives in use, BZP is one of the most common and the most studied compounds (7, 43). In 
the range of dopaminergic BZP activity, observed are motion disorders, hypertension, tremors, 
vomiting, urinary retention, paranoid psychosis. The adrenergic effects of BZP include 
 symptoms such as anxiety, dilated pupils, insomnia, dizziness, hyperventilation, respiratory 
acidosis, palpitations, tachycardia, chest pain,  seizures, hypertension and ischaemia (2, 7). 
From the cholinergic side, after the use of BZP, the following symptoms are observed: xero-
stomia and vomiting, and the emerging  immunological disorders are hypersensitivity 
reactions and pruritus (2). The serotonergic activity of BZP shows effects like agitation, confu-
sion, dissociation states, headache, hangover symptoms, nausea, vomiting, abdominal pain. 
BZP binds to 5-HT1A-D and 5-HT2A-C receptors at the micromolar level (38). It strong-
ly inhibits monoamine reuptake by NET whereas low BZP concentrations induce mono-
amine release by DAT and NET. It inhibits DA reuptake and stimulates NA release for am-
phetamine-like effects (43). Katz et al. (2) pointed out that BZP inhibits SERT serotonin 
transporters and binds as an agonist to 5-HT1 receptors, and in high doses binds to the 
5-HT2 receptor causing a mild hallucinogenic effect. Orsolini et al. (44) noted that the hal-
lucinogenic properties of NPS occur through binding to the 5-HT2A receptor. The binding 
of BZP to 5-HT2B causes gastrointestinal effects: abdominal pain and nausea, whereas 
5-HT3 induction causes the onset of migraine (7). In the rat brain synaptosomes, BZP strong-
ly inhibited DA and NA reuptake, had little effect on 5-HT reuptake, stimulated DA, NA 
release and almost no effect on 5-HT release.
TFMPP and mCPP bind most strongly to serotonin 5-HT1A-D and 5-HT2A-C receptors 
and induce monoamines release by SERT (38). The TFMPP binds selectively to 5-HT1 and 
5-HT2 (43). The secretion of hormones such as ACTH, cortisol and prolactin are also medi-
ated by 5-HT receptors (7). The mCPP strongly inhibits monoamine reuptake via SERT (38). 
In the rat brain, it strongly stimulated the release of 5-HT, DA and NA (7). The effect of mCPP 
as an agonist on 5-HT2C receptors is associated with decreased appetite (45, 46). Activation 
of 5-HT3 receptors may be the cause of nausea induced by mCPP (7). The mCPP and MeOPP 
together strongly inhibited monoamine reuptake. In addition, MeOPP had quite high mono-
amine release activity.
The combination of BZP with TFMPP or mCPP can mimic the ecstasy profile because 
BZP releases DA, and TFMPP and mCPP are serotoninergic agonists (47). The combination 
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of BZP and TFMPP raises DA and 5-HT concentrations similarly to ecstasy. The mCPP 
compared to MDMA has lower efficacy as a DAT and NET inhibitor and lower induction 
of 5-HT release.
Hondebrink et al. (38) have analysed the available data on the neuropharmacological 
and neurotoxicological effects of the large number of NPSs. Researchers pointed out that 
clinical effects should be correlated with estimated concentrations in the human brain. For 
most of the substances, the estimated concentrations in the brain exceed levels in the 
blood. There may be differences of up to several orders of magnitude for different NPSs. 
In the case of the analysed piperazine derivatives, it was noticed that the range of serum 
concentrations and estimated brain concentrations are comparable for BZP, while there are 
differences for TFMPP and mCPP. A summary of these data is presented in Table II. 
Luethi and Liechti (48) examined in vitro the pharmacological profiles of new psycho-
active substances that interact with monoaminergic systems. Researchers used important 
pharmacological data and estimated doses reported by recreational users and doses avail-
able from clinical trials for analysis. The proposed dosage from clinical trials was 100 mg 
for BZP (fixed dose), and 0.5–0.75 mg kg–1 for mCPP. It was found that the inhibition of 
norepinephrine transporter (NET) and dopamine transporter (DAT) was potentially 
strongly correlated with human doses of stimulants used. It is reported that the values of 
these defined inhibitory strengths may be a marker of substance psychoactivity in humans 
and may be useful as predictors for human doses. An additional indicator in such results 
may be the SERT inhibitory potential (serotonin transporter).
Kirla et al. (49) have evaluated toxicity, toxicokinetics and behavioral effects of meta 
chlorophenylpiperazine (mCPP) in zebrafish larvae. They showed higher mCPP toxicity 
compared to cocaine and a negative effect on larvae development. They highlighted the 
similarities and differences between mammal and fish models. They presented the utility 
of zebrafish larvae as a model for screening new psychoactive substances.
In summary, homeostasis is a fundamental index of psychological balance and  general 
health. New psychoactive substances, including piperazine derivatives, affect many different 
neurotransmitter systems. They cause mood changes, psychological and psychobiological 
disorders. The biggest problem is that after a short period of mood increase and increased 
body activity, there is a period of neurochemical exhaustion and a serious health problem 
may develop. Therefore, the desire to understand the full effect of piperazine compounds 
on the human body is fully justified. When NPS enters the drug market, both positive and 
Table II. Concentrations of selected piperazine derivatives determined in human serum and estimated in 
human brain after recreational use (38)
Group Compound Range of serum concentrations 
(μmol L–1)
Range of estimated concentrations 






BZP – N-benzylpiperazine, mCPP – 1-(3-chlorophenyl)piperazine, TFMPP – 1-(3-trifluoromethylphenyl)piperazine
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negative effects are unknown at first. That is why it is important to gather information on 
the structure of psychoactive compounds, effects on the body and selectively differentiate 
the symptoms they cause.
THE EFFECTS OF ABUSE AND HEALTH CONSEQUENCES
Arbo et al. (50) have shown toxic effects of piperazine derivatives against cardiac cells. 
Four compounds were tested: BZP, TFMPP, MeOPP and MDBP among which the TFMPP 
had the strongest cytotoxic activity. The studies were conducted using the H9c2 cell line 
derived from the heart of the rat. In the heart, piperazine derivatives induced cell death by 
disturbing Ca2+ homeostasis, ATP depletion and significant loss of mitochondrial membrane 
potential. A significant reduction in intracellular ATP is a hallmark of hypoxia and toxic 
damage. It was noted that mitochondria play an important role in the induction of cardio-
toxicity by piperazine derivatives. Loss of mitochondrial membrane potential impairs oxida-
tion, phosphorylation, destroys energy and induces cell death. Disorders in Ca2+ homeosta-
sis can cause serious heart rhythm disturbances. The high level of mitochondrial Ca2+ 
triggers the mitochondrial permeability transition pore (MPTP), leads to the collapse of 
mitochondrial membrane potential, discontinuation of ATP production and cell death. A 
neutral red (NR) uptake assay was performed to confirm the results. This test is based on the 
ability of living cells to bind a weak cationic dye. All piperazine designer drugs caused 
concentration-dependent cytotoxic effects. Repetto et al. (51) in their study described neutral 
red uptake assay as one of the most commonly used cytotoxicity tests for primary cells and 
cell lines from various sources. The researchers’ justification of the cardiotoxic effects of pi-
perazine derivatives at the cellular level indicates a high risk of exposure to the health and 
lives of potential consumers (50). Due to the large number of NPS on the drug market, rapid 
cardiotoxicity screening of emerging NPS is necessary (52).
Persona et al. (21) showed the toxic action of BZP on the mitochondrial level in the  human 
glial cell line population LN-18. They presented a significant increase in LDH (lactate dehy-
drogenase), which is a negative prognostic factor. These changes led to excessive produc tion 
of reactive oxygen species, oxidation of lipids, proteins or DNA, and reduction of ATP levels 
in cells. Excessive production of ROS (reactive oxygen species) caused hyperthermia. The 
DNA damage has been demonstrated by analysing the level of the 8-OHdG (8-hydroxy-2’-
deoxyguanosine) marker. In their results, the researchers presented the effect of BZP on an 
increase in caspase-3 activity, which may be a factor inducing cell death. It was noted that 
BZP at the highest concentration caused the activation of caspase-9 related to the mitochon-
drial pathway. It did not affect significantly the activation of caspase-8 related to the receptor 
pathway. These findings indicate that BZP can affect the induction of the mitochondrial path-
way of apoptosis in glial cells. Researchers have shown that organs in which cells have a large 
number of mitochondria are particularly susceptible to the harmful effects of BZP.
Functional magnetic resonance imaging (fMRI) is a technique used in humans to detect 
the effects of BZP and TFMPP on neuronal activation, receptors stimulation and the release 
of neurotransmitters (2, 53). Studies have shown increased activation of the mesolimbic sys-
tem in the nervous system in response to anticipation of rewarding stimuli. Curley et al. (53) 
examined the effects of BZP and TFMPP given separately and in combination at the ex-
pected stage of processing in the reward system. In the brain regions related to people’s reac-
tions to risk and uncertainty changes were observed. The BZP dopaminergic effects seemed 
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to increase the positive agitation and then reduce the reaction to uncertainty whereas 
TFMPP seemed to increase the emotional response.
Researchers from New Zealand have investigated the impact of BZP and TFMPP on 
psychophysiological parameters of information processing in healthy male volunteers (28). 
They showed a negative impact on sensory processing. The study was conducted using 
electroencephalography (EEG), analysing the brain’s bioelectrical activity. In the applied 
test, the potentials evoked by the specific event (event-related potentials, ERP) were mea-
sured (28, 54). Changes in the electric voltage in the brain that occur at the moment of the 
stimulus were analysed. Lee et al. (28) have shown the disruption of the nerve processes 
required to respond to stimuli, such as attention, memory update and auditory informa-
tion processing. Researchers concluded that the observed changes may be related to 5-HT, 
DA and NA transmission disorders caused by the tested compounds.
Zwartsen et al. (22) have examined the effect of piperazine derivatives on spontaneous 
neuronal activity in rats using microelectrode matrices (MEA). All test substances inhibi-
ted neuronal activity depending on the concentration. The possibility of separate struc-
ture-activity relationships (SAR) was indicated, based on the observed wide range of IC50 
(inhibitory concentration). The effects of substances belonging to the same chemical group 
were compared. Among piperazines, the difference between BZP (IC50 values 161 μmol L–1) 
and TFMPP and mCPP (IC50 values of 19 and 32 μmol L–1, resp.) was reported. This differ-
ence was most likely caused by the addition of a halogen moiety on the phenyl ring, which 
increased the binding to target macromolecules. The authors showed that these studies 
could be the first step in combining chemical structures and substance classes in order to 
determine the structure-activity relationship (SAR) even before NPS appears on the market.
Dias-da-Silva et al. (55) have conducted an assessment of the hepatotoxic effects of pi-
perazine derivatives BZP, TFMPP, MeOPP and MDBP. The authors became interested in 
hepatocytes because of their function in the detoxification process. Researchers analysed 
two human liver cell lines (HepaRG and HepG2) and primary rat hepatocytes. They showed 
the harmful effects depending on the type of piperazine derivative and its concentration. 
The strongest cytotoxic activity was caused by TFMPP. For all piperazine derivatives tested, 
it could be observed: intracellular GSH (glutathione) depletion, ATP depletion, oxidative 
stress, loss of mitochondrial membrane potential, caspase-3 activation and cell death. 
Among other things, the authors noted the induced intracellular depletion of GSH caused 
by piperazine designer drugs. The GSSG (glutathione disulphide) formed was moved into 
the extracellular medium to protect cells from oxidative stress. This type of reaction was 
compared with the reactions to amphetamine and MDMA. Similarities have been demon-
strated between these metabolic pathways and the pathways described for piperazines. Gu 
et al. (56) confirmed in their research a previously reported mechanism regarding glutathi-
one (GSH) detoxification for piperazine bioactivation products. They have analysed unusu-
al re-arranged Cys-piperazine (cysteine-piperazine) and Gly-Cys-piperazine (glycine-cyste-
ine-piperazine) adducts in rat and human liver microsomes.  Researchers accepted a 
mechanism for bioactivation of the piperazine ring to obtain an imidazoline derivative. In 
summary, these authors have pointed out that the examined metabolic pathway appeared 
to be a common GSH detoxification mechanism for piperazine bioactivation products.
Recreational usage of products with psychoactive effects have become popular among 
young people. Min et al. (57) noted the risk associated with hormonal disorders and repro-
ductive functions. Their research showed the estrogenic activity of BZP and TFMPP, which 
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Table III. List of health consequences of abuse of piperazine derivatives
Adverse effects of abuse piperazine derivatives Reference(s)
Psychiatric 
disorders
Agitation, anxiety, confusion 
Insomnia, feelings of breakdown 
Fatigue, drowsiness 
Lowered mood, tension, anxiety 
Anxiety, paranoia, depression 
Euphoria/dysphoria 
Mood swings, panic, bad mood 
Hallucinations, especially auditory hallucinations 
Withdrawal from social interactions 
Dissociative symptoms 
1, 2, 7, 27, 38, 43
1, 2, 7, 26, 27
1, 2
2, 7
1, 7, 26, 43
4, 19
25, 27, 37





Increase in systolic and diastolic blood pressure 
Palpitation, circulatory collapse 
Myocardial infarction
Chest pain 
Prolongation of the QT interval 
1, 2, 7, 19, 25, 26
1, 2, 4, 7, 19
2, 7, 26, 27, 43
2, 50, 52







Convulsions, trembling, shaking the body 
Epileptic seizures, repeatability of epileptic seizures 
Increased sensitivity towards light and noise 
Poor concentration 
1, 2, 7, 26, 27, 43
2, 7
1, 2, 7, 25
7
1, 2, 26, 27, 43





Metabolic and respiratory acidosis 






Nausea and vomiting 
Lack of appetite 
Dehydration
Abdominal pain 






Renal failure, acute kidney injury 
2, 7, 43
1, 2, 4, 7
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can be detected at various stages of estrogen signaling pathways from binding to receptors 
to cellular proliferative responses.
Table III shows a list of various health consequences of the abuse of piperazine deri-
vatives being mentioned in last two chapters (1, 2, 4, 5, 7, 8, 19, 21, 25–27, 37, 38, 41, 43, 45, 46, 
50, 52, 55).
In summary, a multidirectional evaluation of the cytotoxic effect of piperazine deri-
vatives was performed. In general, piperazine designer drugs are potentially cardiotoxic, 
hepatotoxic, neurotoxic, neurodegenerative and they are associated with hormonal disor-
ders. It was emphasized that TFMPP showed the greatest cytotoxicity. The problem is that 
new psychoactive substances placed on the market are not subjected to any toxicity and 
teratogenicity tests. Therefore, it is necessary for scientists to do such research. Only by 
covering all aspects of acute and chronic usage of piperazine derivatives the more com-
plete picture of their damaging effects can be presented.
METHODS OF IDENTIFICATION FOR PIPERAZINE DESIGNER DRUGS
In the analysis of piperazine designer drugs, commonly used are methods based on 
modern, coupled techniques, especially chromatographic ones (17). Published analytical 
reports differed in the development of samples and their preparation including hydrolysis 
of conjugates, extraction of analytes (LLE - liquid-liquid extraction, SPE – solid-phase 
 extraction) and derivatization procedures.
Swortwood et al. (58) developed an analytical method using liquid chromatography 
triple quadrupole-tandem mass spectrometry (LCQQQ-MS/MS). The approved method 
was successfully used to analyse two post mortem cases with suspected use of designer 









Abundant sweating, chills 
Bruxism, problems with teeth and jaw 
2
1, 2, 7, 43





Multiple organ failure 
Serotonin syndrome 
Hepatotoxicity 
Attempts to commit suicide 












1, 7, 8, 27
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and TFMPP. Tang et al. (59) carried out the analysis of urine and hair samples, which were 
collected from patients abusing psychostimulants. The test was performed to approve the 
locally developed method using liquid chromatography-tandem mass spectrometry (LC-
MS/MS). Among the identified substances was also TFMPP. Paul et al. (60) have developed 
a liquid chromatography high-resolution mass spectrometry quadrupole-time-of-flight 
(LC-HRMS-QToF) method for the urine analysis in order to identify designer drugs and 
abused drugs. The validation included 39 compounds also related to piperazine deriva-
tives: BZP, mCPP and TFMPP. Concheiro et al. (61) have developed a quantitative method 
targeting 40 novel psychoactive substances, including 8 piperazines and 4 metabolites in 
urine, using liquid chromatography coupled to high-resolution mass spectrometry (LC-
HRMS). Boumrah et al. (5) have developed a qualitative method using gas chromato-
graphy-mass spectrometry, which allows the separation and identification of a mixture 
consisting of piperazine derivatives and amphetamine-type stimulants. Quantitative analysis 
was carried out by high-performance liquid chromatography using a liquid chromato-
graph with a diode-array detector (HPLC-DAD). Gas chromatography-mass spectrometry 
(GC-MS) is a frequently used technique for the identification and determination of pipera-
zine derivatives and their metabolites in body fluids and in available preparations (17, 62, 
63). Beckett et al. (64) used the method of isotope ratio mass spectrometry (IRMS) for the 
determination of the isotope composition of tablets containing BZP and TFMPP. High-
performance liquid chromatography (HPLC) was used to separate BZP and TFMPP. Beckett 
et al. (64) showed the possibility of obtaining information on the origin of designer drugs, 
including BZP and TFMPP by using IRMS. Görgens et al. (36) conducted research to identify 
the highly polar doping compounds used in sports. They developed a method using 
 hydrophilic interaction chromatography coupled with high-resolution mass spectrometry, 
HILIC-HRMS. Among the polar stimulants, BZP was also identified. DeRuiter et al. (65) 
paid attention to the development of numerous designer drug analogues that are not speci-
fically controlled by existing legislation. In their research, they showed the use of GC-MS 
(gas chromatography-mass spectrometry) and GC-IR (gas chromatography-infrared 
spectro scopy) to identify disubstituted piperazine derivatives. Guillou et al. (66) have 
 discussed the problem of the responsibility of customs authorities for the control of goods 
and chemical products entering the European Community market. Recently, Customs 
 authorities reported a large number of NPS being imported from non-European Union 
countries. The routine control performed by the Customs laboratories mainly includes the 
use of GC-MS (gas chromatography-mass spectrometry), FT-IR (Fourier transform infrared 
spectroscopy), NMR (nuclear magnetic resonance), and HR-MS (high-resolution mass 
spectrometry). They showed that modern analytical techniques and cheminformatics tools 
make possible the identification of psychoactive substances apprehended by European 
 Customs. They emphasized the great value of the work of Customs laboratories for the 
protection of public health and the safety of citizens.
A number of other specific methods have been developed for the detection and quan-
tification of analysed compounds. Waite et al. (67) have presented chemiluminescence 
detection of piperazine derivatives using tris(2,2’-bipyridine) ruthenium(III) as a reagent. 
Selected mechanisms of chemical reactions for usage in rapid tests to addictive substanc-
es have already been described in the past (68). Elie et al. (69) have developed microcrystal-
line tests using mercury chloride as a reagent for selected designer drugs, including BZP. 
In the analysed environment, BZP created characteristic flat and square crystals. Philp et 
al. (70) developed and approved a colour method using the NQS (1,2-naphthoquinone-
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4-sulfonate) test reagent to detect piperazine analogs. As a result of the NQS reaction with 
BZP, a bright, orange-red colour specific only to BZP was developed. Piperazine and four 
other piperazine derivatives were also tested: TFMPP, mCPP, pCPP, MeOPP, which also 
showed an orange-red colour. The authors justified the selectivity of NQS reagent and the 
suitability of the method for the initial detection of piperazine analogues. Castaneto et al. 
(19) have evaluated the efficacy of the Randox BAT (biochip array technology) immunoas-
say to identify piperazine derivatives in urine samples. Waddell et al. (71) developed an 
electrochemical, voltammetric method of BZP analysis, whereas Bishop et al. (72) have 
optimized a method using capillary electrophoresis with a chiral selector, for the simul-
taneous separation of amphetamine-like compounds and new stimulants of piperazine 
derivatives group.
The research was also carried out on the effects of formalin solutions and putrefactive 
processes on the analysed compounds (73, 74). Johnson et al. (75) have evaluated the stabi-
lity of selected piperazine derivatives in biological matrices under different storage condi-
tions. They showed that storage conditions can have a big impact on getting the right ana-
lytical results. Lau et al. (76) studied the stability of synthetic piperazines in human blood 
depending on temperature and storage time. They proved that benzyl piperazines were 
more stable than phenyl piperazines. The determinations were made using ultra-fast 
 liquid chromatography with Q-trap electrospray ionization tandem mass spectrometer 
(UFLC-ESI-MS/MS).
In summary, the unambiguous chemical identification of piperazine designer drugs 
requires the use of advanced analytical techniques. In addition, the tests carried out are 
time-consuming and the interpretation of the results requires considerable commitment 
and knowledge. There is no routine analytical approach to piperazine derivatives. That 
creates a research problem. The methodology for determining piperazine designer drugs 
in biological material must be constantly developed. The use of methods using modern 
coupled techniques, especially chromatographic with mass detection, enables comprehen-
sive analysis. By using combined techniques, information can be obtained to defining 
precisely the structure of the tested compounds. Correct identification and quantification 
are necessary for the effective diagnosis and therapy of patients with suspected poisoning.
CONCLUSIONS
New psychoactive substances belong to popular, commonly abused compounds. The 
recreational use of piperazine derivatives can result in acute and chronic health conse-
quences. In addition, it is difficult to predict the behavior of people under the influence of 
psychostimulants. Problems with understanding and processing information can have a 
significant impact on one’s own and social function and quality of life. Potential users of 
designer drugs looking for beneficial effects do not pay attention to the simultaneous 
 occurrence of threats. The development of science and technology allows for a new, inte-
grated approach to diagnosis, proper identification of NPSs and effective assistance for 
poisoning patients. The article presents selected scientific achievements related to pipera-
zine derivatives in designer drugs, obtained in recent years. The presented scientific 
 reports may give the opportunity to analyze the impact of piperazine compounds on the 
human body. They may be as well the basis for further research aimed at solving the diffi-
culties and threats that these compounds bring to the modern world.
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Abbreviations, acronyms, symbols. – 2,3-DCPP – 1-(2,3-dichlorophenyl)piperazine, 2C-B-BZP – 
1-(4-bromo-2,5-dimethoxybenzyl)piperazine, 5-HT – serotonin, 5-HT1A-D – serotonin receptors, 
5-HT2A-C – serotonin receptors, 5-HT3 – serotonin receptors, 8-OHdG – 8-hydroxy-2’-deoxyguanosine, 
ACTH – adrenocorticotropic hormone, BAT – biochip array technology, BZP – N-benzylpiperazine, Cys-
piperazine – cysteine-piperazine, DA – dopamine, DAT – dopamine reuptake transporter, DBZP – 
1,4-dibenzylpiperazine, EMCDDA – European Monitoring Centre for Drugs and Drug Addiction, ERP 
– event related potentials, fMRI – functional magnetic resonance imaging, Gly-Cys-piperazine – glycine-
cysteine-piperazine, GSH – glutathione, GSSG – glutathione disulphide, HILIC-HRMS – hydrophilic 
interaction chromatography coupled with high resolution mass spectrometry, HR-MS – high-resolution 
mass spectrometry, IRMS – isotope ratio mass spectrometry, LC-HRMS – liquid chromatography cou-
pled to high-resolution mass spectrometry, LC-HRMS-QToF – liquid chromatography high-resolution 
mass spectrometry quadrupole-time-of-flight, LC-MS/MS – liquid chromatography-tandem mass spec-
trometry, LCQQQ-MS/MS – liquid chromatography triple quadrupole-tandem mass spectrometry, LDH 
– lactate dehydrogenase, LLE – liquid-liquid extraction, MBZP – 1-benzyl-4-methylpiperazine, MDBP – 
1-(3,4-methylenedioxybenzyl)piperazine, MDMA – 3,4-metylenedioxymetamfetamin (ecstasy), MEA – 
microelectrode matrices, MeBP – 1-(3-methylbenzyl)piperazine, MeOPP – 1-(4-methoxyphenyl)pipera-
zine, MePP – 1-methyl-3-phenylpiperazine, MPTP – mitochondrial permeability transition pore, 
mCPCPP – 1-(3-chlorophenyl)-4-(3-chloropropyl)piperazine, mCPP – 1-(3-chlorophenyl)piperazine, NA 
– noradrenaline, NET – norepinephrine reuptake transporter, NPS – new/novel psychoactive substances, 
NQS – 1,2-naphthoquinone-4-sulfonate, NR – neutral red, pFBP – 1-(4-fluorobenzyl)piperazine, pFPP – 
1-(4-parafluorophenyl)piperazine, SERT – serotonin reuptake transporter, SPE – solid phase extraction, 
TFMPP – 1-(3-trifluoromethylphenyl)piperazine, UFLC-ESI-MS/MS – ultra-fast liquid chromatograph 
with Q-trap electrospray ionization tandem mass spectrometer
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